2022年9月1日 · Bivalirudin increases in a dose-dependent fashion, the PTT, DTT, ACT, PT, and INR. Monitoring for therapeutic effect of bivalirudin will be primarily based upon dilute thrombin time (DTT).
nonsurgical therapy, argatroban and bivalirudin may be assayed using the PTT. The target therapeutic range is 1.5–3.0 times the mean of the laboratory-established reference interval (RI). Blood is collected 4 hours after the initiation of intravenous therapy for bivalirudin or 2 hours after starting argatroban, and the dosage is
Bivalirudin - StatPearls - NCBI Bookshelf
2024年2月28日 · Bivalirudin, a direct thrombin inhibitor, plays a crucial role in the management and treatment of patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction. This comprehensive activity delves into the nuanced aspects of bivalirudin therapy, shedding light on its indications, action, and contraindications.
Bivalirudin – UW Medicine Anticoagulation Services
At UWMC, bivalirudin is monitored using the Direct Thrombin Inhibitor (DTI) assay (Plasma-Diluted Thrombin Time). Used instead of aPTT to monitor injectable DTI therapy. Preferred over aPTT due to better sensitivity, and is not affected by antiphospholipid antibodies. Cost, turnaround time, and 24/7 availability at UWMC are similar to aPTT.
How to best monitor bivalirudin anticoagulant effect for …
Development of suitable, accurate testing for bivalirudin monitoring is paramount to prevent complications. We sought to compare aPTT, aPTT with heparinase (HPTT), dTT1:4, modified dTT1:10, and ECA for monitoring of pediatric ECLS patients anticoagulated with bivalirudin.
Unfractionated heparin (UFH), LMWH, fondaparinux, argatroban, …
2023年4月3日 · Bivalirudin is a synthetic 20-amino acid long peptide designed to mimic the active site of hirudin, an anticoagulant produced by the medicinal leech Hirudo medicinalis. Along with argatroban, it is an intravenous direct thrombin inhibitor. Given its peptide structure, bivalirudin is partially metabolized by serum proteases.
Bivalirudin infusions must be closely monitored to achieve an aPTT 1.5 to 2.5 times baseline or aPTT50-80sec. Medical officers are responsible for monitoring aPTT. Nursing staff may request a medical officer review when aPTT results become available. Medical officers are responsible for prescribing any rate changes in eFluids.
Predicting and evaluating the effect of bivalirudin in cardiac …
We develop two approaches to predict the Partial Thromboplastin Time (PTT) based on bivalirudin infusion rates. The first approach is model free and utilizes regularized regression. It is flexible enough to be used as predictors bivalirudin infusion rates measured over several time instances before the time at which a PTT prediction is sought.
Bivalirudin Anticoagulation Dosing Protocol for Extracorporeal …
Clinical characteristics and changes in activated partial thromboplastin time (aPTT) were evaluated from medical records to determine the efficacy of the dosing protocol. ECMO was initiated for acute respiratory distress syndrome in eight (72.7%) patients and for cardiac arrest in three (27.3%) patients.
Direct Thrombin Inhibitor Resistance and Possible Mechanisms
Bivalirudin is an intravenous (IV) direct thrombin inhibitor (DTI) that directly and reversibly inhibits both circulating and clot-bound thrombin. 1 Bivalirudin is US Food and Drug Administration (FDA)–approved for patients with, or at risk of, heparin-induced thrombocytopenia (HIT) undergoing percutaneous coronary intervention (PCI), patients u...